CG Oncology Inc.
NASDAQ: CGON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Arthur Kuan
- Employees
- 142
- Headquarters
- Irvine, United States
- IPO year
- 2024
- Market cap
- $6.3B
- Website
- https://cgoncology.com
Loading CGON…
Loading profile data…Frequently asked questions about CGON
What does CG Oncology Inc. (CGON) do?
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with...
Where does CGON trade?
CG Oncology Inc. (CGON) trades on the NASDAQ.
What sector is CGON in?
CG Oncology Inc. (CGON) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CG Oncology Inc.?
Arthur Kuan is the chief executive officer of CG Oncology Inc. (CGON).
Where is CG Oncology Inc. headquartered?
CG Oncology Inc. is headquartered in United States.
Does CGON pay a dividend?
CG Oncology Inc. (CGON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CGON go public?
CG Oncology Inc. (CGON) completed its initial public offering in 2024.